Shootman Alex

CEO Alex Shootman sold 42,930 shares of ALKT at $21.92; stock now -45.2% from 52-week high of $40.40

CEO Alex Shootman sold 42,930 shares (42.9K shares) at $21.92 on 2025-12-09, reducing his holdings by 5.1% to 798,633 shares (798.6K shares), for a total value of $941,025.60 ($941.0K). The sale occurred at a material discount: the current price is $22.15, and the stock trades 45.2% below its 52-week high of $40.40, indicating a sustained downtrend. Examining same-ticker history, Shootman's prior 5 sells at ALKT show a timing pattern wherein 4 of 5 prior sales were followed by negative 90-day returns, demonstrating consistent ability to precede declines. Against this backdrop, his continuing to sell into a stock down sharply from recent highs—while the company remains unprofitable with net income of $-14,804,000.00 ($-14.8M) despite 26.1% annual revenue growth—suggests either deliberate reduction of exposure or a data-driven response to deteriorating forward signals. The 30-day change of +13.9% adds complexity, showing a recent rebound that has not reversed the longer-term weakness or the CEO's disposition to reduce holdings.

Alkami CEO Shootman sold 42,930 shares at $25.66 on 2025-09-09; stock now -40.3% from 52-week high amid unprofitable operations.

CEO Shootman sold 42.9K shares for $1.1M on 2025-09-09, reducing holdings by 5.1% to 796.6K shares. The transaction occurred when the stock was already -40.3% from its 52-week high of $42.22, and the current price of $25.19 is 1.8% below the sale price. This marks his second sale in 13 days—he sold 30K shares on 2025-08-27—suggesting active liquidation during a declining period. At his same ticker (ALKT), his prior four measurable sales show 3 of 4 were well-timed at the 90-day horizon, with an overall 90-day timing success rate of 75% at ALKT, higher than his cross-ticker 66.67% rate. The company remains unprofitable (net income $-13.6M latest quarter) despite 26.1% annual revenue growth, creating fundamental uncertainty that may be driving the CEO's recent selling pattern.

CEO Shootman Alex sold 75,000 ALKT shares at $25.20; stock down -39.2% from 52-week high of $42.22.

CEO Shootman Alex sold 75,000 shares (75.0K shares) on 2025-08-27 for $1,889,655.00 ($1.9M), reducing his holdings from 914.5K to 839.5K shares. The stock has declined significantly: -39.2% from its 52-week high of $42.22 and -3.5% over the prior 30 days. Across his cross-ticker track record, his 9 prior sells showed a 62.50% well-timed rate at the 90-day mark, but at ALKT specifically, only 3 of 4 measurable prior sales aligned with subsequent declines, and his most recent ALKT sale on 2025-06-09 has yet to produce a measurable 90-day outcome. The company remains unprofitable with net income of $-13.6M on revenue of $112.1M, though it posted +26.1% annual revenue growth. The CEO's large sale into a materially depressed valuation warrants scrutiny regarding management's assessment of near-term prospects.

CEO Shootman Alex sold 42,930 shares (42.9K) of ALKT at $30.53 for $1.3M on 2025-06-09; stock now down 29.6% from 52-week high.

CEO Shootman Alex sold 42,930 shares at $30.53 on 2025-06-09, reducing his stake by 4.5% to 914,493 shares post-transaction. This sale follows a pattern of recent activity—another sale at ALKT on 2025-05-28 preceded this transaction by 12 days. At the same-ticker level, his prior 4 measurable sales at ALKT produced 3 well-timed outcomes at the 90-day mark, suggesting selective disposal rather than liquidation. The current stock price of $29.72 sits 29.6% below the 52-week high of $42.22, and the company remains unprofitable with net income of $-7.8M against quarterly revenue of $97.8M, though it is growing revenue at 26.1% annually. The timing of this sale relative to the stock's elevated 52-week range and the company's path to profitability warrants monitoring.

CEO Alex Shootman sold 75,000 ALKT shares at $28.99; stock down 32.1% from $42.22 high. Prior ALKT sales 4-of-4 well-timed.

CEO Alex Shootman sold 75,000 shares (75.0K shares) on 2025-05-28 at $28.99, reducing holdings by 7.3% to 957,423 shares (957.4K shares). The transaction occurred while the stock trades -32.1% from its 52-week high of $42.22, and the company remains unprofitable (net income of $-7,816,000.00) despite 26.1% revenue growth. Notably, Shootman's prior four sales at ALKT were all well-timed, with 90-day post-sale declines ranging from -1.9% to -28.8%, and his cross-ticker track record shows a 66.67% well-timed rate across 7 prior sells. The repetition of his sell pattern at this specific ticker—executed during a significant drawdown from 52-week highs—warrants examination of whether this sale reflects forward-looking positioning or capital reallocation amid the company's profitability challenge.

CEO Shootman Alex sold 35,408 shares of ALKT at $24.28 on 2025-03-10; stock down 43.7% from 52-week high, company unprofitable.

CEO Shootman Alex sold 35,408 shares at $24.28 in March, reducing holdings by 3.3% to 1,031,485 shares. The transaction occurred as ALKT is down 40.2% over the past 90 days and 43.7% from its 52-week high of $42.22. At the same-ticker level, the insider's prior three measurable sales at ALKT have been well-timed at the 90-day mark 2 out of 3 times, with the most recent Dec 2024 and Nov 2024 sales preceding further declines of 28.8% and 24.1% respectively. The company remains unprofitable with a net loss of $9,442,000.00 against quarterly revenue of $85,906,000.00. The timing of this sale within a broader downtrend, combined with the insider's demonstrated pattern of well-timed exits at this ticker, warrants close monitoring of near-term price action and broader business fundamentals.

ALKT CEO Shootman sold 75,000 shares (75.0K shares) for $2,230,131.09 on 2025-02-26 at blended $29.74; stock down -16.4% in 30 days.

Alex Shootman, Chief Executive Officer of Alkami Technology, executed 2 separate sales totaling 75,000 shares for $2,230,131.09 on 2025-02-26. This represents a -6.6% reduction in his post-transaction holdings of 1,066,893 shares. The sale occurs against a backdrop of material recent weakness: the stock has declined -16.4% over the 30-day period prior to the filing and -24.9% over 90 days, trading -30.1% below its 52-week high of $42.22. At the same-ticker level, Shootman's prior 4 trades at ALKT show mixed timing outcomes (only 1 of 3 measurable sells were well-timed at the 90-day mark), and his most recent prior sale on 2024-12-09 has already seen a -6.3% decline within 30 days. Fundamentally, Alkami remains unprofitable (latest full-year net income was $-9,442,000.00) despite strong revenue growth of +29.6% year-over-year, which may constrain the risk-reward calculus for existing shareholders.

CEO Shootman Alex sold 39.1K shares of ALKT at $38.32 for $1.5M on 2024-12-09; stock up 34.2% in 90 days yet company unprofitable.

Shootman Alex sold 39,143 shares at $38.32 on 2024-12-09, representing a 4.0% reduction in his holdings to 942,064 shares. The sale occurred as ALKT stock has risen 34.2% over the prior 90 days and trades just 5.8% below its 52-week high of $42.22, suggesting the CEO executed during a period of material appreciation. However, this sale takes place in the context of fundamental weakness: the company generated negative net income of $-9,442,000.00 in its latest quarter and remained unprofitable over its most recent full fiscal year, despite posting annual revenue growth of 29.6%. At the same-ticker level, his prior two completed sales (2024-09-09 and 2024-08-14) both saw subsequent 90-day returns of +35.8% and +23.4% respectively—meaning the stock rose after both prior sales, indicating a pattern of selling before appreciative moves rather than before declines.

CEO Shootman sold 75,000 shares of ALKT for $2.9M at $39.28 on 2024-11-27, retaining 981.2K shares post-sale.

Shootman Alex, as Chief Executive Officer, sold 75,000 shares (75.0K shares) for $2,946,165.00 ($2.9M) at $39.28, reducing his holding by 7.1% to 981,207 shares (981.2K shares). The sale occurred at a price 3.2% above the current market price of $38.06 and near the 52-week high of $42.22, suggesting execution at a favorable valuation relative to recent trading. However, the company remains unprofitable with a net income of $-9,442,000.00 ($-9.4M) in its latest quarter despite strong annual revenue growth of +29.6%, reflecting the tension between top-line momentum and current financial performance. The CEO's prior two trades at this ticker show mixed timing: his 2024-08-14 sale was followed by a +23.4% 90-day return (poorly timed), while his 2024-09-09 sale saw +11.0% 30-day gains with 90-day outcome still pending, suggesting inconsistent execution in choosing exit points at ALKT.

CEO Alex Shootman sold 37,758 shares of ALKT at $29.75 for $1,123,300.50, reducing stake 3.5% to 1,056,207 shares post-transaction.

CEO Alex Shootman sold 37,758 shares at $29.75 on 2024-09-09, reducing his stake from 1,093,965 shares to 1,056,207 shares. The sale occurred near the company's 52-week high of $34.10, with the stock currently trading at $28.87 and down 7.3% over the preceding 30 days. This represents the CEO's second open-market sale at ALKT in recent weeks, following an August 14, 2024 transaction. The company remains unprofitable with negative net income of $-12,317,000.00 in the latest quarter, despite posting 29.6% annual revenue growth to $82,160,000.00. With the CEO retaining 1.06M shares post-transaction, the magnitude of this sale is relatively modest against his overall holdings.